List view / Grid view
Learn what sets Bethyl custom monoclonal antibodies quality and service apart and discover the top reasons why you should choose Forits Life Sciences for your next project.
Complete solutions for neurological disease research and discovery - helping you to better understand diseases to improve patient outcomes.
A screening method called dynamic BH3 profiling can identify potentially effective combinations of existing drugs for personalised cancer therapy, research has shown.
Scientists have found four clinically approved drugs and nine compounds with the potential to be repurposed as therapeutics for COVID-19.
We discuss how liquid handling automation supports drug discovery workflows & highlight opportunities to improve the efficiency and quality of these.
A new high-throughput screening platform has been used to identify two compounds with antiviral activity against the Nipah and Hendra viruses.
Scientists have created a RT-ddPCR assay to analyse both the non-coding and coding RNA regions of SARS-CoV-2.
Learn about a practical, high-throughput method for validating the target-specificity of antibodies for the application of western blot.
A modified luciferase enzyme has been developed as an immunosensor to be fused with a Q-body and used in immunoassays.
28 May 2021 | By Eurofins DiscoverX* and Tecan
In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
A wide range of tools to support your immuno-oncology research and help redefine and develop tailored, life-changing immunotherapies to fight cancer.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
Researchers have successfully created an unbiased, high-throughput microtitration assay for the quantification of Ebola virus in cell lines.
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
